Protein kinase D as a potential new target for cancer therapy |
| |
| Authors: | Courtney R. LaValle Kara M. George Elizabeth R. Sharlow John S. Lazo Peter Wipf Q. Jane Wang |
| |
| Affiliation: | 1. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA;2. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260, USA;3. University of Pittsburgh Drug Discovery Institute, Pittsburgh, PA 15261, USA |
| |
| Abstract: | Protein kinase D is a novel family of serine/threonine kinases and diacylglycerol receptors that belongs to the calcium/calmodulin-dependent kinase superfamily. Evidence has established that specific PKD isoforms are dysregulated in several cancer types, and PKD involvement has been documented in a variety of cellular processes important to cancer development, including cell growth, apoptosis, motility, and angiogenesis. In light of this, there has been a recent surge in the development of novel chemical inhibitors of PKD. This review focuses on the potential of PKD as a chemotherapeutic target in cancer treatment and highlights important recent advances in the development of PKD inhibitors. |
| |
| Keywords: | PKD, protein kinase D DAG, diacylglycerol CaMK, calcium/calmodulin-dependent kinase PH, pleckstrin homology PKC, protein kinase C GPCR, G protein-coupled receptor ERK, extracellular signal-regulated kinase HDAC, histone deacetylase SphK2, sphingosine kinase 2 Hsp, heat-shock protein SSH1L, slingshot 1 like MMP, matrix-metalloproteinase VEGF, vascular endothelial growth factor MEF2, myocyte enhancer factor-2 ECM, extracellular matrix AR, androgen receptor BCC, basal cell carcinoma SCLC, small cell lung cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
